Abstract
Lymphokine-activated killer (LAK)-cell therapy has emerged as a new strategy in designing protocols for the treatment of cancer. However, in its present clinical form, it has not fulfilled the early promise shown in murine models of human metastatic disease. In an attempt to gain understanding as to why this might be the case, we measured the ability of human LAK cells, generated in vitro for 4 days, to kill LAK cells from the same donor that had been exposed to IL-2 in vitro for 8 days, and vice versa. In eight separate experiments using different donors, 4-day ('early') LAK cells were able to kill syngeneic 8-day ('late') LAK cells, while late LAK cells were also able to kill early LAK cells. Strong killing was observed in both directions, which was almost total in one instance. In order to assess the development of this phenomenon, early LAK cells were tested for their ability to kill syngeneic LAK cells that were 1, 2, 3 or 4 days 'older' and the reciprocal experiment conducted using late LAK cells as effectors. The results illustrate a strong capacity for the development of syngeneic killing by human LAK cells. The possible implications of this phenomenon for the clinical administration of LAK cell/IL-2 therapy are discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Al-Azzawi F., Smith J., Stimson W. H. Immunoscintigraphy of metastases with radiolabelled human antibodies. Br Med J (Clin Res Ed) 1987 Feb 28;294(6571):545–546. doi: 10.1136/bmj.294.6571.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Al-Azzawi F., Stimson W. H., Govan A. D. Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines. J Clin Lab Immunol. 1987 Feb;22(2):71–75. [PubMed] [Google Scholar]
- Brooks B., Rees R. C. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Clin Exp Immunol. 1988 Nov;74(2):162–165. [PMC free article] [PubMed] [Google Scholar]
- Damle N. K., Doyle L. V., Bradley E. C. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986 Nov 1;137(9):2814–2822. [PubMed] [Google Scholar]
- Gallagher G., Wilcox F., al-Azzawi F. Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells. Clin Exp Immunol. 1988 Nov;74(2):166–170. [PMC free article] [PubMed] [Google Scholar]
- Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kalland T., Belfrage H., Bhiladvala P., Hedlund G. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol. 1987 Jun 1;138(11):3640–3645. [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4:681–709. doi: 10.1146/annurev.iy.04.040186.003341. [DOI] [PubMed] [Google Scholar]